Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slow-Release ASA vs Normal Release ASA in Chronic Coronary Disease
NCT00501254Phase 3Completed
- Sponsor
- Rottapharm Biotech
- Start
- Feb 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in coronary artery disease (CAD) (2 arms), sponsored by Rottapharm Biotech. Primary endpoints: Thromboxane/prostacyclin balance at 1 year and Platelet aggregation at 1 year. Started Feb 2005; status: completed.
02
Drugs
aspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00501254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501254.